Vetirus Pharmaceuticals Acquires Enso Discoveries to Expand Regenerative Medicine Portfolio

Naples, Florida-based Vetirus Pharmaceuticals, a global company with headquarters also in London, UK, has announced its acquisition of Enso Discoveries, LLC, a biotech firm based in Manhattan, Kansas, specializing in regenerative medicine. The acquisition was disclosed during the 10th annual Animal Health, Nutrition, and Technology Innovation Europe event.

Vetirus Pharmaceuticals is known for its biologic therapies in human and veterinary health. The acquisition of Enso Discoveries is seen as a strategic move to improve the company’s ability to provide innovative and cost-effective solutions to benefit animals and humans worldwide.

Enso Discoveries is recognized for its cutting-edge products like Rebound PRP™ and Rebound PRF®, which are widely utilized in veterinary and human health sectors. These patented regenerative medicine kits offer accessible and proven therapies to support optimal healing processes.

Robert Jordan, Vetirus Pharmaceuticals’ CEO, highlighted the significance of this acquisition, stating that it aligns with the company’s mission to redefine global healthcare solutions. The acquisition includes the transfer of Enso Discoveries’ intellectual property portfolio, including patents for their flagship products, Rebound PRP™ and Rebound PRF®.

The financial details of the acquisition have not been disclosed. However, both companies have confirmed that the deal involves the complete transfer of Enso Discoveries’ intellectual property. The acquisition is structured to ensure a smooth operational transition and to leverage Vetirus Pharmaceuticals’ global infrastructure for the expansion of Rebound High-Performance PRP.

This acquisition demonstrates Vetirus’ dedication to advancing regenerative medicine and expanding its global presence. By integrating Enso Discoveries’ expertise into its offerings, Vetirus aims to accelerate research and development efforts and deliver groundbreaking therapies in veterinary and human health sectors.

Vetirus Pharmaceuticals is committed to a seamless integration process and aims to enhance production capabilities, broaden market reach for existing products, and explore new applications for regenerative medicine technologies. The company assures uninterrupted service for current customers during this transitional phase.